Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Beryl Drugs Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Beryl Drugs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Beryl Drugs Ltd. - AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2025

    30 May 2025, 8:40PM AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2025
  • Beryl Drugs Ltd. - Board Meeting Outcome for OUTCOME OF BOARD MEETING

    30 May 2025, 8:06PM OUTCOME OF BOARD MEETING
  • Beryl Drugs Ltd. - Board Meeting Intimation for TO CONSIDER AND APPROVE AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MAR

    19 May 2025, 10:31PM Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and appr
  • Beryl Drugs Ltd. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    16 Apr 2025, 1:12PM As of March 2025, 26.38% is owned by Indian Promoters and 73.62% by Public. <p align=justify> Top four Promoters holding highest number of shares of B
  • Beryl Drugs Ltd. - COMPLIANCE CERTIFICATE UNDER REGULATION 40(9)

    12 Apr 2025, 11:30PM COMPLIANCE CERTIFICATE
  • Beryl Drugs Ltd. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Apr 2025, 1:32PM COMPLIANCE CERTIFICATE UNDER REGULATION 74(5)
  • Beryl Drugs Ltd. - COMPLIANCE CERTIFICATE FOR THE QUARTER ENDED 31ST MARCH, 2025

    9 Apr 2025, 1:31PM COMPLIANCE CERTIFICATE
  • Beryl Drugs Ltd. - Compliance-57 (5) : intimation after the end of quarter

    9 Apr 2025, 1:19PM NON APPLICABILITY CERTIFICATE
  • Beryl Drugs Ltd. - Integrated Filing (Financial)

    3 Mar 2025, 8:06PM Integrated filing (financial)

Key fundamentals

Evaluate the intrinsic value of Beryl Drugs Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 14.0172 12.6085 12.5872 12.2693 12.3306
Liabilities 14.0172 12.6085 12.5872 12.2693 12.3306
Equity 5.0937 5.0937 5.0937 5.0936 5.0936
Gross Profit 2.2788 1.9451 0.408 1.4482 0.9053
Net Profit 0.7686 0.766 -0.659 0.2396 0.0479
Cash From Operating Activities 0.8203 2.4804 -0.2867 0.3777 0.1847
NPM(%) 2.87 2.84 -4.51 1.7 0.37
Revenue 26.7296 26.8878 14.6037 14.0929 12.8151
Expenses 24.4508 24.9427 14.1957 12.6446 11.9098
ROE(%) 8.63 8.6 -7.4 2.69 0.53

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Beryl Drugs Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 803.05 -0.45 26.62 10.52 301.39 0.62
Lotus Eye Hospital and Institute Ltd 72.28 0.33 205.43 38.33 3.55 0.00
Bharat Immunological and Biologicals Corporation Ltd 25.50 -1.01 0.00 79.58 -39.50 0.00
Astec Lifesciences Ltd 671.00 -0.89 0.00 36.14 -687.10 0.00

Company Info

1994 -The company was incorporated as a medicine pharmaceutical manufacturer. 2007 -The board of directors of the company at its meeting held on Nov.16, 2007 decided to issue 1.50 million equity shares and 2 million warrants to promoters and other strategic investors on preferential basis. -Board of the company had increased the authorized share capital of the company from Rs 5.50 crores to Rs 10.00 crores. 2008 -Board of directors of the company had approved to issue 35 lacs warrants to promoters and other strategic investors on preferential basis. 2015 -Beryl Drugs, MPPHSCL sign deal worth Rs 11.8 crores.

1994 -The company was incorporated as a medicine pharmaceutical manufacturer. 2007 -The board of directors of the company at its meeting held on Nov.16, 2007 decided to issue 1.50 million equity shares and 2 million warrants to promoters and other strategic investors on preferential basis. -Board of the company had increased the authorized share capital of the company from Rs 5.50 crores to Rs 10.00 crores. 2008 -Board of directors of the company had approved to issue 35 lacs warrants to promoters and other strategic investors on preferential basis. 2015 -Beryl Drugs, MPPHSCL sign deal worth Rs 11.8 crores.

Read More

Parent Organisation

Beryl Drugs Ltd.

Founded

24/08/1993

Managing Director

Mr.Sanjay Sethi

NSE Symbol

FAQ

The current price of Beryl Drugs Ltd is

The 52-week high for Beryl Drugs Ltd is

The market capitalization of Beryl Drugs Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Beryl Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Beryl Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Beryl Drugs Ltd shares.

The CEO of Beryl Drugs Ltd is Mr.Sanjay Sethi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT